Medication errors and associated serious outcomes in COVID-19 antivirals: a real-world study based on FDA Adverse Event Reporting System database
Therapeutic Advances in Drug Safety
Published online on January 02, 2026
Abstract
Therapeutic Advances in Drug Safety, Volume 17, January-December 2026.
Background:The Food and Drug Administration (FDA) authorized three COVID-19 antivirals, including remdesivir, nirmatrelvir/ritonavir, and molnupiravir. Although medication errors involving these treatments have been reported, national-level evidence on ...
Background:The Food and Drug Administration (FDA) authorized three COVID-19 antivirals, including remdesivir, nirmatrelvir/ritonavir, and molnupiravir. Although medication errors involving these treatments have been reported, national-level evidence on ...